Airvo for Cell Transplants

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Cross Cancer Institute, Edmonton, Canada
Cell Transplants
Airvo - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to find out what effects of high heated humidity has on you and your mucositis.

Treatment Effectiveness

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: During treatment (up to 14 days)

Day 14
Mucositis severity
The comparison will be weight at admission vs weight at discharge
Change in Patient weight

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Standard of Care
1 of 2
Intervention using the Airvo device
1 of 2
Active Control
Experimental Treatment

84 Total Participants · 2 Treatment Groups

Primary Treatment: Airvo · No Placebo Group · Phase 2

Intervention using the Airvo device
Device
Experimental Group · 1 Intervention: Airvo · Intervention Types: Device
Standard of CareNoIntervention Group · 1 Intervention: Standard of Care · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: during treatment (up to 14 days)
Closest Location: Cross Cancer Institute · Edmonton, Canada
Photo of Edmonton 1Photo of Edmonton 2Photo of Edmonton 3
2011First Recorded Clinical Trial
0 TrialsResearching Cell Transplants
405 CompletedClinical Trials

Who is running the clinical trial?

AHS Cancer Control AlbertaLead Sponsor
176 Previous Clinical Trials
35,896 Total Patients Enrolled
Lisa LemPrincipal InvestigatorCross Cancer Institute, Alberta Health Services

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to participate in the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.